Report Information More information from: https ://www.wis eguyreports .com/reports /495854
Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin ReceptorLike Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016 Report / Search Code: WGR495854
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016’, provides in depth analys is on MelaninConcentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted pipeline therapeutics . The report provides comprehens ive information on the Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for MelaninConcentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - The report reviews Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like
Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for MelaninConcentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding MelaninConcentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 4 Lis t of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) Overview 6 Therapeutics Development 7 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Stage of Development 7 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Therapy Area 8 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Indication 9 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Products Glance 10 Early Stage Products 10 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Companies 11 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) Therapeutics As s es s ment 13 As s es s ment by Monotherapy/Combination Products 13 As s es s ment by Mechanis m of Action 14 As s es s ment by Route of Adminis tration 15 As s es s ment by Molecule Type 16 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Companies Involved in Therapeutics Development 17 Albany Molecular Res earch, Inc. 17 As traZ eneca Plc 18 Boehringer Ingelheim GmbH 19 LEO Pharma A/S 20 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Drug Profiles 21 ALB-127158(a) - Drug Profile 21 Product Des cription 21 Mechanis m Of Action 21
R& D Progres s 21 AZ -13483342 - Drug Profile 23 Product Des cription 23 Mechanis m Of Action 23 R& D Progres s 23 AZ D-3857 - Drug Profile 24 Product Des cription 24 Mechanis m Of Action 24 R& D Progres s 24 BI-186908 - Drug Profile 25 Product Des cription 25 Mechanis m Of Action 25 R& D Progres s 25 Small Molecules to Antagonize MCHR1 for Weight Los s - Drug Profile 26 Product Des cription 26 Mechanis m Of Action 26 R& D Progres s 26 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Dormant Projects 27 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) Dis continued Products 29 Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH1R or Somatos tatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Featured News & Pres s Releas es 30 Oct 03, 2011: AMRI Pres ents Final Phas e I Clinical Studies Res ults Of Obes ity Compound At 29th Annual Scientific Meeting Of Obes ity Society 30 May 31, 2011: AMRI Announces Succes s ful Completion Of Phas e I Clinical Study Of Obes ity Compound 30 May 19, 2011: AMRI To Pres ent Phas e I Clinical Res ults Of Obes ity Compound At European Congres s On Obes ity 31 Jul 21, 2010: AMRI Initiates Phas e I Study Of ALB-127158(a) For Treatment Of Obes ity 31 Jun 02, 2009: AMRI Advances New Obes ity Drug MCH-1 Receptor Antagonis t Toward IND Submis s ion 32 Appendix 34 Methodology 34 Coverage 34 Secondary Res earch 34 Primary Res earch 34 Expert Panel Validation 34 Contact Us 34 Dis claimer 35 Lis t of Tables Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analys is by Early Stage Products , H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Products under Development by Companies , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 13 Number of Products by Stage and Mechanis m of Action, H1 2016 14 Number of Products by Stage and Route of Adminis tration, H1 2016 15 Number of Products by Stage and Molecule Type, H1 2016 16 Pipeline by Albany Molecular Res earch, Inc., H1 2016 17 Pipeline by As traZ eneca Plc, H1 2016 18 Pipeline by Boehringer Ingelheim GmbH, H1 2016 19 Pipeline by LEO Pharma A/S, H1 2016 20 Dormant Projects , H1 2016 27 Dormant Projects (Contd..1), H1 2016 28 Dis continued Products , H1 2016 29 Lis t of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analys is by Early Stage Products , H1 2016 10 As s es s ment by Monotherapy/Combination Products , H1 2016 13 Number of Products by Stage and Mechanis m of Actions , H1 2016 14 Number of Products by Stage and Routes of Adminis tration, H1 2016 15 Number of Products by Stage and Molecule Type, H1 2016 16
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349